期刊文献+

苦楝中的三萜类和甾体成分及其抗糖尿病活性研究 被引量:4

Triterpenoids and sterols from Melia azedarach and their anti-diabetes activities
原文传递
导出
摘要 目的研究苦楝Meliaazedarach皮的化学成分及其抗糖尿病活性。方法运用正相、反相及SephadexLH。20凝胶柱色谱等方法分离纯化化合物,通过波谱数据和理化性质鉴定结构,并测试所得化合物体外对葡萄糖激酶(GK)、组蛋白去乙酰化酶SIRTl激动活性和二肽基肽酶IV(DPPIV)、11β-羟基类固醇脱氢酶(11β-HSD)的抑制活性。结果从苦楝皮甲醇提取物中分离得到6个三萜和3个甾体化合物,分别鉴定为meliastatin3(1)、苦楝酸(2)、苦楝萜酮内酯(3)、sendanolactone(4)、南岭楝酮B(5)、20,24.环甘遂烷-7(8).烯-1613,21α,25-三羟基-3.酮(6)、3β-羟基.5,8-环氧麦角甾.6,22-二烯(7)、2p,3β,4β-三羟基-孕甾-16-酮(8)、3β-羟基-孕甾.5,17(20)-二烯-16.酮(9)。化合物2对人11β-HSDI的IC50值为54.15nmol/L。结论化合物6~9为首次从该植物中分离得到,受试化合物1~4均未表现出GK、SIRT1体外激动活性和DPPIV抑制活性,但化合物2对人11β-HSD具有良好的选择性。 Objective To investigate the chemical constituents from the barks of Melia azedarach and their antidiabetes activities. Methods The constituents were isolated and purified by silica gel, reverse phase silica gel, and Sephadex LH-20 column chromatography, and their structures were identified by spectra and physiochemical characteristic analysis. The agonist activities of the isolated triterpenoids against glucokinase (GK) and SIRT1, and the inhibitory activity against dipeptidyl peptidaseslV (DPPIV), and 11 β-hydroxysteroid dehydrogenase (11β-HSD) were tested in vitro. Results Six triterpenoids and three sterols were obtained from MeOH extract in the barks ofM. azedarach and were elucidated as meliastatin 3 (1), kulonic acid (2), kulactone (3), sendanolactone (4), dubione B (5), 20, 24-cyclotirucalla-7(8)-en-16β, 21α, 25-trihydroxy-3-one (6), 3β- hydroxy-5, 8-epidioxy-ergosta-6, 22-diene (7), 2β, 3β, 4β-trihydroxy-pregn-16-one (8), and 3[3-hydroxy-pregn-5, 17 (20)-dien-16-one (9). Compound 2 showed the inhibitory activity against 11 β-HSD 1 with the IC50 value of 54.15 nmol/L. Conclusion Compounds 6---9 are obtained from this species for the first time. The tested compounds 1--4 are inactive against GK, SIRT1, and DPPIV, but compound 2 shows high selectivity against human 11 β-HSD.
出处 《中草药》 CAS CSCD 北大核心 2014年第7期913-918,共6页 Chinese Traditional and Herbal Drugs
基金 国家自然科学基金资助项目(81360477) "973"计划前期研究专项(2011CB512005) 国家重点实验室培育基地--广西壮族自治区药用资源化学与药物分子工程重点实验室基金(CMEMR2012-B05) 2012年度广西高等学校优秀人才资助计划
关键词 苦楝 三萜 甾体 葡萄糖激酶 SIRT1 二肽基肽酶IV 11Β-羟基类固醇脱氢酶 Melia azedarach L. triterpenoids sterols glucokinase SIRT1 dipeptidyl peptidases IV 11β-hydroxysteroid dehydrogenase
  • 相关文献

参考文献18

  • 1汪建辉,欧瑜.葡萄糖激酶与糖尿病[J].药物生物技术,2012,19(6):552-556. 被引量:15
  • 2Milne J C, Lambert P D, Schenk S, et al. Small molecule activatiors of SIRTI as therapeutics for the treatment of type 2 diabetes [J]. Nature, 2007, 450(7170): 712-716.
  • 3李文斌,崔美玉,许冬梅,关广聚.二基肽酶Ⅳ酶活性与糖尿病肾病的相关性[J].山东大学学报(医学版),2010,48(3):12-14. 被引量:4
  • 4Morton N M, Holmes M C, Fiévet C, et al. Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11β-hydroxysteroid dehydrogenase type 1 null mice [J]. JBiol Chem, 2001, 276(44): 41293-41300.
  • 5中国科学院中国植物志编辑委员会.中国植物志[M].北京:科学出版社,1997.162-167.
  • 6中国药典[S].2010年版.一部.39-40,189,32.
  • 7Aoudia H, Ntalli N, Aissani N, et al. Nematotoxicphenolic compounds from Melia azedarach against Meloidogyne incognita [J]. J Agrie Food Chem, 2012, 60(47): 11675-11680.
  • 8Faizi S, Wasi A, Siddiqui B S, et al. New terpenoids from the roots of Melia azedarach [J]. Aust J Chem, 2002, 55(4): 291-296.
  • 9韩玖,林文翰,徐任生,汪文陆,赵善欢.苦楝化学成份的研究[J].药学学报,1991,26(6):426-429. 被引量:14
  • 10Vijayanand S, Wesely E G. Evaluation of antidiabetic activity of Melia azadirach on alloxan induced diabetic rats [J]. IntJ Curt Pharm Res, 2011, 3(4): 37-40.

二级参考文献45

  • 1林善锬.糖尿病肾病发病机制的几个关键[J].中华老年多器官疾病杂志,2002,1(3):165-167. 被引量:3
  • 2肖梅芳,张学梅,白香,谭焕然.不同糖尿病模型小鼠糖原代谢变化的研究[J].中国临床药理学与治疗学,2005,10(6):613-616. 被引量:23
  • 3涂晓文,陈香美.结缔组织生长因子:糖尿病肾病治疗的新靶点[J].国际泌尿系统杂志,2006,26(1):126-129. 被引量:1
  • 4欧阳礼枝,陆付耳,刘文军,高志强,徐丽君.小檗碱对胰岛素抵抗大鼠肝脏葡萄糖激酶及其调节蛋白的影响[J].世界华人消化杂志,2007,15(8):885-889. 被引量:17
  • 5Egawa S I, Watanabe Y, Kikuya Y, et al. Dipeptidyl pepfidase from human serum: purification, characterization, and N2 terminal aminoacid sequence [J].J Biochem, 1998, 124:428-433.
  • 6Patrick J Boyle, Jeffrey S. Application of incretin minmotics and dipeptidyl Peptidase IV inhibitors in managing type 2 diabetes mellitus [ J ]. JAOA, 2007 ( 107 ) : 10-16.
  • 7Daniel J. Dipeptikyl peptidase-4 inhibition and the treatment of type 2 diabetes [J].Diabetes Care, 2007, 30: 1335-1343.
  • 8Herman G A, stein P P, Thomberry N A, et al. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes : focus on sitagliptin [ J ]. Clinical Pharmacology and Therapeutics, 2007, 81:761-767.
  • 9Deacon C F, Hughes T E, Hoist J J. Dipeptidyl peptidase Ⅳ inhibition potentiates the insulinotropic effect of glucagons-like peptide 1 in the anesthetized pig [ J ]. Diabetes, 1998, 47:764-769.
  • 10Pederson R A, White H A, Schlenzig D, et al. Improved glucose tolerance in Zucker fatty rats by oral administra- tion of the dipeptidyl peptidase Ⅳ inhibitor isolercine thiazolidide[J]. Diabetes, 1998, 47 : 1253-1258.

共引文献993

同被引文献63

引证文献4

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部